Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
btsc mrna-loaded dendritic cell vaccine
- Development stage
- Phase 1
- Lead developer
- Duke University
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal
01
Overview
BTSC mRNA-loaded DCs is an autologous, personalized dendritic cell vaccine designed for the treatment of recurrent glioblastoma multiforme (GBM). Developed by John Sampson and colleagues at Duke University, the therapy involves harvesting a patient's own dendritic cells and loading them with messenger RNA (mRNA) derived from brain tumor stem cells (BTSCs), specifically those expressing the CD133 marker. These stem cells are believed to be responsible for tumor recurrence and resistance to standard therapies. By presenting BTSC-specific antigens, the vaccine aims to prime the patient's immune system to recognize and eliminate the tumor-propagating cell population. In cases where specific BTSC RNA cannot be isolated in sufficient quantities, total tumor RNA (ttRNA) is utilized as an alternative antigen source.
- Other names
- BTSC mRNA-loaded dendritic cell vaccineCD133+ BTSC RNA-loaded DCsRecurrent GBM Stem Cell Tumor Amplified RNA Immunotherapy
02
Targets
HLA-B7MHC II (Major histocompatibility complex class II receptor)
Beyond the preview
Go deeper on btsc mrna-loaded dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on btsc mrna-loaded dendritic cell vaccine.